Summary

Beam is preparing to open a state-of-the-art Manufacturing facility located on Davis Drive in RTP, NC and will be looking for Manufacturing and Quality professionals to join our team. Please submit your resume here to be considered for positions that we will be opening in Q4 2022 and throughout 2023. We are looking for fearless innovators who are passionate about helping patients and looking to join a collaborative environment where you will be able to have a direct impact on getting our facility up and running.

Job description

Beam is preparing to open a state-of-the-art Manufacturing facility located on Davis Drive in RTP, NC and will be looking for Manufacturing and Quality professionals to join our team. Please submit your resume here to be considered for positions that we will be opening in Q4 2022 and throughout 2023. We are looking for fearless innovators who are passionate about helping patients and looking to join a collaborative environment where you will be able to have a direct impact on getting our facility up and running.

Requirements

Experience in biotechnology or related fields
Manufacturing and quality professionals
Innovative and collaborative
Passionate about advancing therapeutic editing strategies

Company overview

Beam Therapeutics is a pioneering biotechnology company focused on developing precision genetic medicines through base editing technology. Founded by leading CRISPR researchers, the company leverages its proprietary base editing platform to create therapies that can make precise, single-letter changes to DNA without causing double-strand breaks. Beam's innovative approach addresses genetic diseases at their source by correcting point mutations that cause various inherited disorders. The company's pipeline includes programs targeting sickle cell disease, beta-thalassemia, and other genetic conditions. Beam Therapeutics represents the next generation of gene editing companies, building upon CRISPR technology to enable more precise and potentially safer genetic modifications. The company has established strategic partnerships and collaborations to advance its therapeutic programs and expand the applications of its base editing technology across multiple disease areas.